Alexandra Gerlach, Associate Editor

Erin Lexner, PharmD, BCPS, discussed her team’s experience transitioning to outpatient BEAM from inpatient CBV.

Shelby Quinn, PharmD, BCOP shares insights about treatment using osimertinib in early lines.

Imlunestrant is an investigational, brain-penetrating, oral selective degrader of estrogen receptor.

Pharmacists share key insights about the use of ADCs for treatment of breast cancer.

Christine Barrett, PharmD, BCOP, shares insights, challenges, and advice for oncology pharmacists navigating neoadjuvant therapy.

Jessica Davis, PharmD, BCOP highlights the role of pharmacy technicians in ambulatory oncology clinic settings.

Lauren Dietz, PharmD, highlighted the role of oncology pharmacists in guiding prophylaxis decisions to optimize transplant outcomes.

Julia Ziegengeist, PharmD, BCOP offers insights for pharmacists navigating adjuvant and neoadjuvant treatment of breast cancer.

Amir Ali, PharmD, BCOP, and Allison Hsieh, PharmD share insights from their presentation about cytokine release syndrome, ICANS, and CAR T-cell therapy.

Alexandra Wolff, PharmD, BCOP, FHOPA, was awarded a fellow of HOPA at the 2025 annual meeting.

Mya Tran, PharmD, BCOP, offers insights for navigating the complex treatment landscape for non-small cell lung cancer.

Michael Arnold, PharmD, discussed the role of oncology pharmacists in enhancing biomarker testing for patients with metastatic colorectal cancer.

Erin Harrell, PharmD, offers insights about managing peripheral neuropathy in patients receiving bortezomib.

Enriqueta Felip, MD, PhD, discussed the benefits of subcutaneous pembrolizumab for patients with metastatic non–small cell lung cancer.

Fatty acid metabolism plays a critical role in treatment responses.

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, offers insights for oncology pharmacists treating patients with metastatic esophageal squamous cell carcinoma.

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, discusses a case study of a patient with metastatic esophageal squamous cell carcinoma.

The trial showed that adding pelabresib to ruxolitinib improved outcomes in myelofibrosis with manageable adverse effects.

CAV-1 is a key protein in lipid rafts that helps control cellular processes such as growth, survival, and migration.

Siremadlin is a novel, investigational, second-generation antagonist that binds to MDM2.

The predictive tool may reveal the mechanisms underlying treatment resistance in patients with HER+ breast cancer.

Real-time profiling of T-cell activation states in non-CAR T-cells may help guide treatment decisions.

Pharmacists performed weekly toxicity and tumor lysis syndrome monitoring.

John Ostrominski, MD shares insights into the safety and efficacy of finerenone, based on data from the FINEARTS-HF trial.

The CDC reports 483 total cases across 20 states as of March 28, 2025.

Sarah Spinler, PharmD, FCCP, FAHA, FASHP, AACC, discussed management of atrial fibrillation in patients with cancer.

Anna Sophie Mueller, MD discusses how imaging could advance risk identification in cardiovascular care.

Marc Humbert, MD, PhD, shared data that were presented at the ACC 2025 Scientific Sessions.

Jawad Butt, MD, offers insight into his analysis of the FINEARTS-HF trial.

John Buse, MD, PhD discusses the expanding role of GLP-1 receptor agonists in treatment of cardiovascular conditions.